NIH, FDA Launch Database for Parkinson’s Disease Precision Medicine

The Accelerating Medicines Partnership (AMP) program for Parkinson’s disease (PD) has launched a data portal to help researchers develop precision medicine therapies for the condition. The portal includes de-identified data collected from 4,298 patients with Parkinson’s and will enable researchers to study complex data sets and perform genome-wide analyses. AMP PD is a public-private partnership between NIH, the FDA, and industry and non-profit organizations. AMP PD aims to transform and accelerate drug development for Parkinson’s by providing the expertise and support needed to identify which biomarkers have the greatest potential to predict PD and progression of the disease.